Kyongbo Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Kyongbo Pharmaceutical Co Ltd working capital to net assets ratio. Kyongbo Pharmaceutical Co Ltd (214390) has a Working Capital to Net Assets ratio of -16.1% as of June 2026. Working capital of ₩-23.65 Billion (current assets of ₩169.90 Billion minus current liabilities of ₩193.55 Billion) is measured against net assets of ₩146.99 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Kyongbo Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Kyongbo Pharmaceutical Co Ltd (2014–2025)
Working capital to net assets ratio of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. This chart shows how Kyongbo Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at -16.1%, reflecting working capital of ₩-23.65 Billion against net assets of ₩146.99 Billion KRW. See Kyongbo Pharmaceutical Co Ltd (214390) liquidity interval to measure how many days the company can operate on defensive assets alone.
Kyongbo Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2014–2025)
Kyongbo Pharmaceutical Co Ltd working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Kyongbo Pharmaceutical Co Ltd from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Kyongbo Pharmaceutical Co Ltd.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 8.2% | ₩11.89 Billion | ₩145.74 Billion | ₩159.14 Billion | ₩147.25 Billion | ▼ -5.0 pp |
| 2024 | 13.2% | ₩19.28 Billion | ₩146.15 Billion | ₩151.94 Billion | ₩132.66 Billion | ▲ +1.0 pp |
| 2023 | 12.2% | ₩17.64 Billion | ₩144.38 Billion | ₩135.90 Billion | ₩118.26 Billion | ▼ -2.2 pp |
| 2022 | 14.4% | ₩20.76 Billion | ₩143.70 Billion | ₩116.33 Billion | ₩95.57 Billion | ▼ -0.9 pp |
| 2021 | 15.3% | ₩22.35 Billion | ₩145.70 Billion | ₩111.17 Billion | ₩88.81 Billion | ▼ -13.1 pp |
| 2020 | 28.5% | ₩44.43 Billion | ₩156.06 Billion | ₩138.19 Billion | ₩93.76 Billion | ▲ +1.4 pp |
| 2019 | 27.1% | ₩40.36 Billion | ₩149.16 Billion | ₩124.18 Billion | ₩83.81 Billion | ▼ -13.0 pp |
| 2018 | 40.0% | ₩59.62 Billion | ₩149.01 Billion | ₩128.94 Billion | ₩69.32 Billion | ▲ +4.5 pp |
| 2017 | 35.5% | ₩50.26 Billion | ₩141.51 Billion | ₩110.64 Billion | ₩60.38 Billion | ▲ +12.7 pp |
| 2016 | 22.8% | ₩29.51 Billion | ₩129.40 Billion | ₩102.23 Billion | ₩72.72 Billion | ▼ -10.2 pp |
| 2015 | 33.0% | ₩40.57 Billion | ₩122.82 Billion | ₩105.11 Billion | ₩64.54 Billion | ▲ +15.7 pp |
| 2014 | 17.4% | ₩11.86 Billion | ₩68.33 Billion | ₩97.48 Billion | ₩85.62 Billion | — |